Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 4 of 7
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
MMI (Medical Microinstruments, Inc.)
NCT07178210
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
Mclean Hospital
NCT04075435
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
University College, London
NCT06372821
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
NeuroPro Therapeutics
NCT07222878
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
Bernard (Barry) Baumel
NCT06781333
ED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care
NYU Langone Health
NCT06079203
Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias
Anne Murray
NCT07224139
Changing Talk Online Training (CHATO) National Trial
University of Kansas Medical Center
NCT04610944
The Brain Health Study: A Pragmatic, Patient-Centered Trial
Kaiser Permanente
NCT05356702
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company
NCT05026866
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company
NCT04437511
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
AriBio Co.
NCT05531526
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
AdventHealth Translational Research Institute
NCT05379348
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
Eli Lilly and Company
NCT02951598
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
Tharick Pascoal
NCT05361382
Minnesota Inclusive LTSS for LGBTQ Seniors
University of Minnesota
NCT05530590
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Cognito Therapeutics
NCT05637801
BRINK (BRain In Kidney Disease) Memory Study 2.0
Anne Murray
NCT04975464
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Acumen Pharmaceuticals
NCT06335173
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
Janssen Research & Development
NCT04619420
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
Washington University School of Medicine
NCT04699786
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
C2N Diagnostics
NCT06025877
A Study of Caregiver Connections Via Technology in Dementia
Mayo Clinic
NCT05779839
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Merck Sharp & Dohme
NCT06721156
The PorchLight Project
University of Minnesota
NCT05550727
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Eli Lilly and Company
NCT06538116
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
Northwestern University
NCT03960476
A Spanish-language Caregiver-Enabled Care Program
Ceresti Health
NCT06631144
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
Rush University Medical Center
NCT04337255
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Actinogen Medical
NCT06125951
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
Ono Pharmaceutical Co.
NCT06881836
Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
NYU Langone Health
NCT04784416
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Weill Medical College of Cornell University
NCT03649724
Effects of Dance and Music Appreciation on Brain Health and Fitness in People at Risk for Alzheimer's Disease
Wake Forest University Health Sciences
NCT05507905
Sleep Aging and Risk for Alzheimer's 2.0
NYU Langone Health
NCT03278119
Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
University of Pennsylvania
NCT05393388
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
Noah Pharmaceuticals
NCT06597058
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
University of Michigan
NCT05584241
Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias
Louisiana State University Health Sciences Center Shreveport
NCT05060848
Developing a Communication Intervention for People With Memory Challenges and Their Care Partners
Weill Medical College of Cornell University
NCT05143255
High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
Massachusetts Institute of Technology
NCT04042922
Music, Social Attention, and Dementia
University of California, San Francisco
NCT06768996
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
HiDO Technologies
NCT06691256
A Scalable Nutrition Adherence Intervention
Florida State University
NCT06121986
Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
Washington University School of Medicine
NCT05731440
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Mayo Clinic
NCT02740634
Multi-Center Study of Sensory Stimulation to Improve Brain Function
Cognito Therapeutics
NCT03556280
Investigation of Inflammation Using [C-11]-CS1P1
Tammie L. S. Benzinger, MD, PhD
NCT04517552
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Boston University
NCT03560960
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
University of California, San Diego
NCT03703856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.